USA

The acquisition gives Zymeworks access to Yupelri, an FDA-approved, once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD) that Theravance markets in partnership with Viatris.

Gavi has indicated that proposals involving vaccine production in Africa will receive particular consideration as part of broader efforts to strengthen regional manufacturing capacity.

The announcement came during Moderna’s Science Day, where the biotechnology company outlined plans to broaden its pipeline across oncology, rare diseases, and immune-mediated disorders.

Through the HELM Cluster, the emirate has brought together research institutions, advanced healthcare infrastructure, genomics programs, manufacturing capabilities, and distribution networks within a single ecosystem.

The announcement follows growing calls from public health advocates and humanitarian organizations urging the US government to share available supplies of MBP134 to support outbreak control efforts in Central Africa.

The acquisition is expected to strengthen Merck’s position in the rapidly growing life sciences sector, particularly in areas such as cell and gene therapy, precision diagnostics, multi-omics research, and biopharmaceutical manufacturing.

Evaluators examined how the hospital manages patient care across multiple departments, including safety protocols, infection control, medication handling, and continuous quality improvement processes.

The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.

Under the agreement, Biogen will integrate RayThera’s portfolio of anti-inflammatory and immune-modulating candidates into its broader research and development engine.

Researchers will assess the drug’s efficacy and safety in patients with acute coronary syndrome (ACS), recent myocardial infarction, ischemic stroke, and peripheral arterial disease.